Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 4/20 | 0.48 |
| ▸ | UTS2R | Q9UKP6 | 12/20 | 0.46 |
| ▸ | CTSA | P10619 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5926540 | 0.96 | CTSA (0.47) | CYP26A1UTS2RCTSA | |
| SCHEMBL5926624 | 0.95 | CYP26A1 (0.46) | CYP26A1UTS2RCTSA | |
| SCHEMBL5926437 | 0.94 | CYP26A1 (0.47) | CYP26A1UTS2RCTSA | |
| SCHEMBL5927525 | 0.89 | KMT2A (0.52) | CYP26A1UTS2RCTSA | |
| SCHEMBL5927193 | 0.88 | CTSA (0.48) | CYP26A1UTS2RCTSA | |
| SCHEMBL5926672 | 0.87 | ITGB1 (0.49) | — | |
| SCHEMBL5927342 | 0.83 | UTS2R (0.46) | CYP26A1UTS2RCTSA | |
| SCHEMBL5926616 | 0.83 | MMP1 (0.49) | CYP26A1CTSA | |
| SCHEMBL5926430 | 0.82 | ITGB1 (0.48) | UTS2R | |
| SCHEMBL5926620 | 0.82 | ITGB1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. | 2006-12-07 | — | — | US | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | CYP26A1 2632/4885UTS2R 3251/4885CTSA 638/4885 |
| US-20060276518-A1 | Aryl and heteroaryl compounds and methods to modulate coagulation | TFPI, F9, F2 | CYP26A1 526/4885UTS2R 2544/4885CTSA 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.